Mikhail Blagosklonny is an oncologist, author and a professor at Roswell Park Cancer Institute. He possesses vast knowledge in cancer, cellular, and molecular biology, as well as clinical investigations. His specialties include cell cycle, anticancer therapeutics, mitosis, tumor suppressors, and signal transductions among others.
His involvement in the age-related diseases and aging has helped him reveal anti-aging drugs such as rapamycin. Mikhail Blagosklonny holds a Medical Doctorate in internal medicine from the First Pavlov State Medical University of St. Petersburg.
Mikhail Blagosklonny has vast experience in the medical field following his work at research and medical education institutions in the United Sates. In 2002, he worked at New York Medical College as an Associate Professor of Medicine.
He later joined Ordway Research Institute in Albany New York as a Senior Scientist. He later got an appointment at Roswell Park Cancer Institute as an oncologist professor following his knowledge in the cancer biology and therapy. Additionally, Mikhail is an author of more than 170 research work, book chapters, and reviews.
According to Research Gate, Mikhail Blagosklonny is an editor of several publications of Cell Cycles, PLOS ONE, Cell Death and Differentiation, Autophagy, and Cancer Research as well as Cancer Biology and Therapy. He has also edited journals such as the American Journal of Pathology and International Journal of Cancer.
Rosewell Park Cancer Institute
Rosewell Park Cancer Institute is a New York-based medical facility that deals with cancer research and treatment. The institution, which is a member of the National Comprehensive Cancer Network, carries out clinical research and develops new drugs for the treatment of different types of cancer in adults and children.
Mikhail Blagosklonny’s role in the institution includes formulation of new anti-cancer therapies, as well as various methods of preventing cancer. He also engages the fellow workmates in the institution in developing new ideas on normal cell protection during chemotherapy and radiotherapy.
Role of mTOR in Aging and Cancer
According to Mikhail Blagosklonny, molecular damage or any other random damage is not the primary cause of aging and cancer. He cites that the inflammatory activity of the hypothalamus that increases with age could be the cause of aging. The Target of Rapamycin (mTOR) promotes cellular mass growth, and when the developmental stage comes to a halt, the aging process begins.
mTOR leads to increased functioning of the cell in the body leading to an increase in the secretion produced by fibroblasts that alter the normal equilibrium of the body. A change in the body’s balance leads to age-related diseases resulting to death.